Vaccine Development and Manufacturing

Takeda will invest more than 100 million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.

The company plans to expand access to its Prevanar 13 vaccine in humanitarian emergency settings.

Research by agency scientists may help speed development of Zika virus vaccines.

The study in 48 healthy adults will assess the safety and immunogenicity of a prime-boost regime of two different intranasal doses of the RSV vaccine, SynGem.

German biotech ARTES and Iranian biopharma manufacturer BioSun will develop an HPV vaccine.

Insulin has been shown to improve the production of viruses and viral vectors.

The companies will collaborate the manufacture of personalized cancer vaccines.

HHS entered into a contract with BioProtection Systems Corp. for commercial manufacturing tests of an Ebola vaccine.

The hospital received a five-year $5 million grant from CDC to survey for communicable diseases in children and evaluate vaccine effectiveness.

Zika vaccine development is hindered by technical challenges and funding shortfalls.

The Phase I trial will test Bavarian Nordic’s vaccine, which is manufactured using a vaccine vector based on smallpox.

The vaccine candidate has also won a Priority Medicines (PRIME) status from EMA.

The company will collaborate with the Walter Reed Army Institute of Research to co-develop a Zika vaccine candidate.

Two recently published studies suggest that pre-exposure to the dengue virus (DENV) could predict a person’s reaction to the Zika virus (ZIKV) because of of the antigenic similarity between the viruses. One study was published on June 23, 2016 in Nature Immunology and the other on June 27, 2016 in Proceedings of the National Academy of Sciences of the United States of America (PNAS). Dengue and Zika are both mosquito-borne flaviviruses that are cross-reactive.

MilliporeSigma and the International Vaccine Institute in Seoul, South Korea aim to develop more robust, scalable vaccine manufacturing processes.

Studying broadly neutralizing antibodies in infants may lead to new pathways in HIV vaccine development.

A new indication for Emergent BioSolutions’ BioThrax will give the drug market exclusivity through November 2022.

The vaccine alternative, manufactured with a GE FlexFactory system, could be associated with fewer adverse reactions than the live vaccine option

Phase I clinical trials of PfSPZ revealed it may protect healthy adults, who have not been exposed to Malaria before, for more than on year.

MilliporeSigma expands its Carlsbad, California-based GMP capacity for viral and gene-therapy products by nearly 90%.

Traditional methods of measuring the effectiveness of vaccines against the flu are called into question by new findings from the NIH.

Even though the organizers of New York’s Tribeca Film Festival decided not to air the anti-vaccine film by discredited British researcher Andrew Wakefield, the so-called documentary is getting a healthy run and further perpetuating the myth of a link between childhood vaccination and autism.

Collaboration and single-use technologies aided the rapid scale-up of Ebola vaccine manufacturing

Proven science-based strategies can help to accelerate vaccine development.

Global outbreaks energize vaccine R&D and drive production modernization.